(Q110424723)

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

title

Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies (English)

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

author

Patrycja Nowak-Sliwinska

series ordinal

3

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

1

Magdalena Rausch

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

author name string

Paul J. Dyson

series ordinal

2

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

publication date

28 June 2019

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

published in

Advanced Therapeutics

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

volume

2

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

issue

9

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

5 January 2022

page(s)

1900042

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042

Antimetastatic activity of novel ruthenium (III) pyridine complexes

5 January 2022

cites work

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Harnessing the potential of epigenetic therapy to target solid tumors.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Epigenetic therapy in gastrointestinal cancer: the right combination

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Allosteric cross-talk in chromatin can mediate drug-drug synergy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Real-time, in vivo measurement of tissular pO2 through the delayed fluorescence of endogenous protoporphyrin IX during photodynamic therapy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The ruthenium complex cis-(Dichloro)Tetraammineruthenium(III) chloride presents immune stimulatory activity on human peripheral blood mononuclear cells

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Photodynamic therapy of cancer: an update

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

In vitro effects of binuclear (η (6)-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Ruthenium(II) Polypyridyl Complexes as Photosensitizers for Antibacterial Photodynamic Therapy: A Structure-Activity Study on Clinical Bacterial Strains

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A).

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Nucleosome acidic patch-targeting binuclear ruthenium compounds induce aberrant chromatin condensation

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

In vivo measurement of tissue oxygenation by time-resolved luminescence spectroscopy: advantageous properties of dichlorotris(1, 10-phenanthroline)-ruthenium(II) hydrate

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Organometallic ruthenium(II) arene compounds with antiangiogenic activity

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Cisplatin in cancer therapy: molecular mechanisms of action

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Challenges and successes in developing new therapies for hepatitis C.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Ru(II) Compounds: Next-generation anticancer metallotherapeutics?

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The chicken chorioallantoic membrane model in biology, medicine and bioengineering

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

In vivo anti-tumor activity of the organometallic ruthenium(ii)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

New ruthenium(II)-letrozole complexes as anticancer therapeutics

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Liposomal cisplatin: a new cisplatin formulation

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Metal complexes in cancer therapy - an update from drug design perspective

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

5 January 2022

Cancer genome landscapes

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Towards improved therapeutic CORMs: understanding the reactivity of CORM-3 with proteins

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Arene ruthenium complexes as anticancer agents

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Editorial: Looking beyond the obvious

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

A novel class of ruthenium-based photosensitizers effectively kills in vitro cancer cells and in vivo tumors.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Drug Delivery Strategies for Platinum-Based Chemotherapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Synthesis, characterization, and biological evaluation of new Ru(II) polypyridyl photosensitizers for photodynamic therapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Arene ruthenium(ii) complex, a potent inhibitor against proliferation, migration and invasion of breast cancer cells, reduces stress fibers, focal adhesions and invadopodia

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The emerging quest for the optimal angiostatic combination therapy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Site selectivity of platinum anticancer therapeutics

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Metal-based drugs that break the rules

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Beyond mouse cancer models: Three-dimensional human-relevant in vitro and non-mammalian in vivo models for photodynamic therapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The development of RAPTA compounds for the treatment of tumors

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Immunotherapy for colorectal cancer: where are we heading?

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Metal Drugs and the Anticancer Immune Response

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Novel computational approaches to polypharmacology as a means to define responses to individual drugs

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Binding of Organometallic Ruthenium(II) and Osmium(II) Complexes to an Oligonucleotide: A Combined Mass Spectrometric and Theoretical Study†

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

In vitro immunomodulatory activity of ruthenium complexes

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Prospects for combining targeted and conventional cancer therapy with immunotherapy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Consensus guidelines for the use and interpretation of angiogenesis assays

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Role of chromatin damage and chromatin trapping of FACT in mediating the anticancer cytotoxicity of DNA-binding small molecule drugs.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Biochemical and biophysical characterization of ruthenation of BRCA1 RING protein by RAPTA complexes and its E3 ubiquitin ligase activity.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Photodynamic therapy for polypoidal choroidal vasculopathy

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Molecular mechanisms of cisplatin resistance

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Cellular processing of platinum anticancer drugs

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

A review of ruthenium complexes activities on different steps of the metastatic process in breast cancer cells.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.

5 January 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Interaction of the NAMI-A complex with nitric oxide under physiological conditions

23 October 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Platinum(IV) antitumour compounds: their bioinorganic chemistry

23 October 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

Oxaliplatin-induced damage of cellular DNA

23 October 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

The Concept of Immunological Surveillance

23 October 2022

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/ADTP.201900042

24 October 2022

Identifiers

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1002/adtp.201900042